AV Node Isolation in Atrial Fibrillation vs. Modulation by "Pace and Ablate" Strategy

AV-node ablation (AVNA) is a common therapy option for rate control strategy of permanent atrial fibrillation with numerous side effects. The investigators hypothesised that an isolation of the AV node is concomitant with less occurrence of new bundle brunch blocks, more frequent preservation and higher rate of escape rhythm compared to AVNA. This retrospective study includes 20 patients being treated with AV-node isolation (AVNI) and 40 historical AVNA-controls. Among others these two methods were compared regarding escape rhythm, delta QRS, procedure time, ablation points, fluoroscopy time and total dose area product (DAP).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation AV Node Ablation Arrhythmias, Cardiac Cardiovascular Diseases Escape; Rhythm Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum

Bad Oeynhausen, 32545, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

paroxysmal, persistend or permanent atrial fibrillation; indication for AVNA

Exclusion criteria

other indications for AVNA than atrial fibrillation as AVNRT, atrial flutter, atrial tachycardia

Treatment and study plan

AV-node isolation

Procedure

Abaltion performed in the right atrium isolating the AV-node from the atrium

Other names: AVNI

AV-node ablation

Procedure

Right sided ablation of the AV-node

Other names: AVNA

Primary outcomes

AV-node escape rhythm

Time frame: intraoperative, follow-up after 1 to 3 month
bundle branch blocks

Time frame: intraoperative, follow-up after 1 to 3 month

Sponsors and collaborators

Lead sponsor

Heart and Diabetes Center North-Rhine Westfalia

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Apr 26, 2021
Registry last updated: Aug 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed